All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
In particular, management highlighted growth in Repatha and Evenity, which delivered 45% and 36% growth even as they have reached 2024 sales of $2.22B and $1.56B respectively. Among Amgen's top ...
Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...
The adjustments related primarily to noncash amortization of intangible assets and fair value step-up of inventory acquired from business acquisitions.
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
Prolia (osteoporosis) and Xgeva (fracture prevention in cancer patients) saw $6.6 billion in combined sales in 2024 but look vulnerable to biosimilars in 2025. To address these headwinds ...
Amgen Earnings: Raising Our Fair Value by 5% on Solid 2025 Guidance and Diversified Growth Prospects
Why it matters: Amgen's performance in 2024 was in line with our estimates ... Research and development expenses are growing faster than sales, but other operating expense cost controls from ...
9d
Zacks.com on MSNAMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical HoldAMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results